



## **TNXB-Related Classical-Like Ehlers-Danlos Syndrome**

Synonyms: Classical-Like Ehlers-Danlos syndrome (cEDS) Type 1, *TNXB*-Related cEDS, *TNXB*-Related Classic-Like Ehlers-Danlos Syndrome

Fleur S van Dijk, MD, PhD,<sup>1</sup> Neeti Ghali, MBChB, MD,<sup>1</sup> Serwet Demirdas, MD, PhD,<sup>2</sup> and Duncan Baker, MSc<sup>3</sup>

Created: September 15, 2022.

### **Summary**

#### **Clinical characteristics**

The clinical features of *TNXB*-related classical-like Ehlers-Danlos syndrome (cEDS) strongly resemble those seen in classic EDS (cEDS). Affected individuals have generalized joint hypermobility, hyperextensible skin, and easy bruising, but do not have atrophic scarring, as is seen in cEDS. There are also several other distinguishing clinical findings including anomalies of feet and hands, edema in the legs in the absence of cardiac failure, mild proximal and distal muscle weakness, and axonal polyneuropathy. Vaginal, uterine, and/or rectal prolapse can also occur. Tissue fragility with resulting rupture of the trachea, esophagus, and small and large bowel has been reported. Vascular fragility causing a major event occurs in a minority of individuals. Significant variability in the severity of musculoskeletal symptoms and their effect on day-to-day function between unrelated affected individuals as well as among affected individuals in the same family has been reported. Fatigue has been reported in more than half of affected individuals. The severity of symptoms in middle-aged individuals can range from joint hypermobility without complications to being wheelchair-bound as a result of severe and painful foot deformities and fatigue.

#### **Diagnosis/testing**

The diagnosis of *TNXB*-related cEDS is established in a proband with suggestive clinical findings and biallelic pathogenic variants in *TNXB* identified by molecular genetic testing.

**Author Affiliations:** 1 North West Thames Regional Genetics Service, London North West University Healthcare NHS Trust; Department of Metabolism, Digestion and Reproduction, Genetics and Genomics Section, Imperial College London, London, United Kingdom; Email: fleur.dijk@nhs.net; Email: neeti.ghali@nhs.net. 2 Clinical Geneticist, Department of Clinical Genetics, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands; Email: s.demirdas@erasmusmc.nl. 3 Sheffield Diagnostic Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom.

## Management

*Treatment of manifestations:* Non-weight-bearing exercise, physical therapy, and careful selection of analgesic medication to address joint pain; if pain is severe or debilitating, consider referral to a pain management specialist or clinic. The use of opioid medication should be avoided for chronic pain, as this does not lead to long-term pain relief and has the potential for addiction issues. Long-term chronic pain may result in the need for mental health services. Prompt assessment and management in a tertiary center is required for bowel rupture, arterial rupture, or organ rupture. Ascorbic acid (vitamin C) may reduce easy bruising but has no effect on the key characteristics of skin hyperextensibility and joint hypermobility. DDAVP® (deamino-delta-D-arginine vasopressin) may also be useful to normalize bleeding time in those with easy bruising. Standard treatment is applicable for joint dislocations, subjective muscle weakness, and cardiac abnormalities.

*Prevention of primary manifestations:* Maintenance of a health body weight; low threshold for referral to gastroenterologist for evaluation of gastrointestinal symptoms; special attention during general anesthesia in order to provide adequate positioning and support as well as being aware of tissue fragility, which has been reported after intubation. Avoid invasive procedures unless absolutely medically necessary; consider carrying medical information or wearing jewelry denoting an increased risk of tissue fragility.

*Surveillance:* Routine follow up ideally with rheumatologist, pain management clinic, and/or specialized EDS services, if available.

*Agents/circumstances to avoid:* Sports with heavy joint strain, as well as contact sports; invasive procedures unless they are absolutely medically necessary; acetylsalicylate (aspirin) and long-term use of NSAIDs; use of opioid medication for chronic pain.

*Pregnancy management:* It is important that the obstetrician and midwives are made aware of the diagnosis of cEDS during a pregnancy. Reported pregnancy and postpartum issues in affected women include miscarriage, premature rupture of membranes, post- or peripartum hemorrhage, and prolapse of the rectum, vagina, and/or uterus. Specialist delivery is strongly advised in view of reported trachea rupture during intubation and esophagus rupture after insertion of a transesophageal ultrasound probe.

## Genetic counseling

*TNXB*-related cED is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for a *TNXB* pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the familial pathogenic variants. Once the *TNXB* pathogenic variants have been identified in an affected family member, carrier testing and prenatal/preimplantation genetic testing are theoretically possible.

## Diagnosis

Minimum suggestive clinical diagnostic criteria for *TNXB*-related classical-like Ehlers-Danlos syndrome (cEDS) were published in the 2017 revised Ehlers-Danlos syndrome nosology [Malfait et al 2017] ([full text](#)), and include all three major criteria AND a family history compatible with autosomal recessive inheritance (see Suggestive Findings).

## Suggestive Findings

*TNXB*-related cEDS **should be suspected** in individuals with a combination of the following major, minor, and family history criteria [Malfait et al 2017].

### Major criteria

- Skin hyperextensibility with velvety skin texture and absence of atrophic scarring (See Figure 1.)
  - Hyperextensibility can be objectively measured by pinching the cutaneous and subcutaneous layers of skin located in the middle of the volar surface of the nondominant forearm and stretching it to at least 1.5 cm or at least 1 cm on the volar surface of the hand (palm).
  - For the neck, elbow, and knees, the stretched measurement should be at least 3 cm.
- Generalized joint hypermobility with or without recurrent dislocations (most commonly shoulder and ankle)
  - Generalized joint hypermobility is typically measured using a Beighton score (see Classic Ehlers-Danlos Syndrome, [Table 1](#); Malfait et al [2017]).
  - A score of  $\geq 5$  at some point in life is considered positive.
- Easy or spontaneous bruising of the skin

### Minor criteria

- Hand anomalies including:
    - Acrogeric hands (characterized by thinning and wrinkling of the skin) with excessive skin
    - Mallet finger(s) (See Figure 2.)
    - Clinodactyly
    - Brachydactyly
  - Atrophy of the muscles in the hands and feet
  - Foot anomalies including:
    - Broad/plump forefoot
    - Brachydactyly with excessive skin
    - Pes planus
    - Hallux valgus (See Figure 3.)
    - Piezogenic papules
  - Edema in the legs in the absence of cardiac failure
  - Mild proximal and distal muscle weakness
  - Axonal polyneuropathy
  - Vaginal, uterus, and/or rectal prolapse
  - Predisposition to tissue fragility, particularly of the gastrointestinal tract (a feature usually suggestive of vascular Ehlers-Danlos syndrome; see Differential Diagnosis.)
- Note: This finding was proposed as an additional important feature of *TNXB*-related cEDS by Green et al [2020] but was not included in the 2017 revised Ehlers-Danlos syndrome nosology [Malfait et al 2017].

**Family history** is compatible with autosomal recessive inheritance (e.g., affected sibs and/or parental consanguinity). Absence of a known family history does not preclude the diagnosis [Malfait et al 2017].

## Establishing the Diagnosis

The diagnosis of *TNXB*-related cEDS **is established** in a proband with suggestive clinical findings and biallelic pathogenic (or likely pathogenic) variants in *TNXB* identified by molecular genetic testing (see Table 1). See Molecular Genetics for more information about the technical challenges related to genetic testing for this gene.

Note: (1) Per ACMG/AMP variant interpretation guidelines, the terms "pathogenic variants" and "likely pathogenic variants" are synonymous in a clinical setting, meaning that both are considered diagnostic and both



**Figure 1.** Hyperextensible skin at the elbow

can be used for clinical decision making [Richards et al 2015]. Reference to "pathogenic variants" in this section is understood to include any likely pathogenic variants. (2) Identification of biallelic *TNXB* variants of uncertain significance (or identification of one known *TNXB* pathogenic variant and one *TNXB* variant of uncertain significance) does not establish or rule out a diagnosis of this disorder.

Molecular genetic testing approaches can include a combination of **gene-targeted testing** (single-gene testing, multigene panel) and **comprehensive genomic testing** (exome sequencing, genome sequencing) depending on the phenotype. Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic testing does not. Individuals with the distinctive findings described in Suggestive Findings are likely to be diagnosed using gene-targeted testing (see Option 1), whereas those in whom the diagnosis of *TNXB*-related cEDS has not been considered are more likely to be diagnosed using genomic testing (see Option 2).

### Option 1

When the phenotypic and family history findings suggest the diagnosis of *TNXB*-related cEDS, molecular genetic testing approaches can include **single-gene testing** or use of a **multigene panel**:



**Figure 2.** Mallet finger (digit 5)

- **Single-gene testing.** Sequence analysis \* of *TNXB* is performed first to detect small intragenic deletions/insertions and missense, nonsense, and splice site variants. Note: Depending on the sequencing method used, single-exon, multiexon, or whole-gene deletions/duplications may not be detected. If only one or no variant is detected by the sequencing method used, the next step is to perform gene-targeted deletion/duplication analysis to detect exon and whole-gene deletions or duplications.

\* See Molecular Genetics for technical considerations pertaining to sequence analysis for this gene due to the *TNXA* pseudogene.

- **An Ehlers-Danlos syndrome or connective tissue disorders multigene panel** that includes *TNXB* and other genes of interest (see Differential Diagnosis) is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) *TNXB* exome analysis can be complicated by the *TNXA* pseudogene; see Molecular Genetics. (2) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (3) Some multigene panels may include genes not associated with the condition discussed in this *GeneReview*. (4) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (5) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests. Copy number variant analysis should be performed to detect deletions/duplications, which have been reported in affected individuals [Demirdas et al 2017].

For an introduction to multigene panels click [here](#). More detailed information for clinicians ordering genetic tests can be found [here](#).



**Figure 3.** Flat, broad feet with left hallux valgus and bilateral hammer toes of digits 2-4

## Option 2

When the phenotype is indistinguishable from many other inherited disorders characterized by connective tissue findings, comprehensive genomic testing may be considered.

**Comprehensive genomic testing** does not require the clinician to determine which gene is likely involved. **Exome sequencing** is most commonly used; **genome sequencing** is also possible.

For an introduction to comprehensive genomic testing click [here](#). More detailed information for clinicians ordering genomic testing can be found [here](#).

**Table 1.** Molecular Genetic Testing Used in *TNXB*-Related Classical-Like Ehlers-Danlos Syndrome

Gene <sup>1</sup>	Method	Proportion of Pathogenic Variants <sup>2</sup> Detectable by Method
<i>TNXB</i>	Sequence analysis <sup>3, 4, 5</sup>	>90% <sup>6</sup>
	Gene-targeted deletion/duplication analysis <sup>7, 8</sup>	<10% <sup>6</sup>

1. See Table A. Genes and Databases for chromosome locus and protein.

2. See Molecular Genetics for information on variants detected in this gene.

3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click [here](#).

4. Consideration must be given to the sequence analysis of the *TNXA* pseudogene homolog region of *TNXB*; *TNXB*-specific primers may be designed and/or a long-range PCR assay performed. Two overall approaches exist: Sanger sequencing analysis of the entire gene or next-generation sequencing plus Sanger sequencing for the pseudogene homolog region.

5. Note that certain DNA variants characterize the recurrent *TNXA/TNXB* gene conversion events; namely, the c.12174C>G; p.Cys4058Trp (NM\_019105.8) and the 120-bp deletion (c.11435\_11524+30del) variants (NG\_008337.2) together characterize *TNXA/TNXB* (CAH-X chimera 1), and c.12174C>G (p.Cys4058Trp) alone is characteristic of *TNXA/TNXB* (CAH-X chimera 2). Detection of these variants should trigger investigation for a likely gene conversion [Morissette et al 2015].

6. Data derived from the subscription-based professional view of Human Gene Mutation Database [Stenson et al 2020]

7. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include a range of techniques such as quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications. Gene-targeted deletion/duplication testing will detect deletions ranging from a single exon to the whole gene; however, breakpoints of large deletions and/or deletion of adjacent genes (e.g., those described by Chen et al [2016]) may not be detected by these methods. Smaller and larger deletions of *TNXB* have been reported in affected individuals [Demirdas et al 2017].

8. In 20%-30% of individuals with severe salt-wasting congenital adrenal hyperplasia (CAH), deletions of *CYP21A2* are identified as a result of unequal crossover events during meiosis. These deletions are categorized into two subtypes: CAH and CAH-X. Three distinct CAH-X chimeras impair *CYP21A2* and *TNXB*. Biallelic CAH-X leads to both CAH and *TNXB*-related cEDS.

**Other laboratory findings.** In the past, detection of tenascin-X in serum was performed and reported to be absent in individuals with *TNXB*-related cEDS [Schalkwijk et al 2001]. However, no diagnostic laboratory currently offers this test.

## Clinical Characteristics

### Clinical Description

*TNXB*-related classical-like Ehlers-Danlos syndrome (cEDS) was first reported in 1997 [Burch et al 1997]. It was noted that the clinical features of these individuals strongly resembled classic EDS (cEDS) because of hyperextensible skin and generalized hypermobility, with two key differences: (1) absence of atrophic scarring and (2) autosomal recessive inheritance. Due to the clinical resemblance with cEDS, updated nosology has renamed the condition classical-like EDS (cEDS) [Malfait et al 2017]. Since the first publications, other features have been reported in individuals with cEDS that are more specific to cEDS [Brady et al 2017, Demirdas et al 2017]. These are reflected in the minor criteria for cEDS and include broad feet and hands, brachydactyly, edema in the legs in the absence of cardiac failure, and predisposition to tissue fragility, particularly of the gastrointestinal tract [Green et al 2020].

To date, 56 individuals from 44 families have been identified with *TNXB*-related cEDS [Burch et al 1997, Schalkwijk et al 2001, Lindor & Bristow 2005, Voermans et al 2007, Voermans et al 2009, Besselink-Lobanova et al 2010, O'Connell et al 2010, Hendriks et al 2012, Péniisson-Besnier et al 2013, Sakiyama et al 2015, Demirdas et al 2017, Micale et al 2019, Rymen et al 2019, Brisset et al 2020, Green et al 2020, Watanabe et al 2021]. The

following description of the phenotypic features associated with this condition is based on these reports. It is important to note that the majority of affected individuals were diagnosed in adulthood.

**Table 2.** *TNXB*-Related Classical-Like Ehlers-Danlos Syndrome: Frequency of Select Features

Feature	% of Persons w/Feature <sup>1</sup>	Comment
Hyperextensible skin	100%	
Joint hypermobility	100%	W/or w/o recurrent joint (sub)luxations
Easy bruising	91%	<ul style="list-style-type: none"> <li>• Likely 100%, as not all reports commented on this feature</li> <li>• Also incl hematomas/ecchymoses</li> </ul>
Foot abnormalities ( $\geq 1$ ) <sup>2</sup>	81%	<ul style="list-style-type: none"> <li>• Most specific: broad foot w/brachydactyly</li> <li>• Most common: pes planus</li> </ul>
Complaints of fatigue	53%	
Subjective muscle weakness	37%	
Vascular fragility	27%	3/56 persons (5%) experienced major medical events due to vascular fragility.
Edema in legs in absence of cardiac failure	25%	
Vaginal/uterus/rectal prolapse	21%	
Hand anomalies	20%	Only brachydactyly was considered.
Gastrointestinal fragility	16%	Incl esophageal, small bowel, &/or large bowel ruptures
Axonal polyneuropathy	14%	Feature was not investigated in the Green et al [2020] cohort of 20 persons.
Other fragility	4%	<ul style="list-style-type: none"> <li>• Trachea rupture after intubation</li> <li>• Defect of nasal cartilages after nose blowing</li> </ul>
Atrophy of muscles in hands & feet	4%	Feature was not investigated in the Green et al [2020] cohort of 20 persons.

1. Not all reports commented on all the clinical features mentioned above. When not commented on, the feature was considered absent.

2. Including broad/plump forefoot, brachydactyly with excessive skin, pes planus, hallux valgus, and painful soles of the feet

**Skin.** People with *TNXB*-related cEDS invariably have hyperextensible skin.

- Although absence of atrophic scarring is one of the features that distinguishes *TNXB*-related cEDS from cEDS, mild atrophic scarring (not including cigarette paper scarring and hemosiderosis) has been reported in seven affected individuals.
- Easy bruising is reported in the majority of affected individuals. In one individual a suspicion of nonaccidental injury had been raised due to excessive bruising.
- Hematomas are frequently encountered.

**Musculoskeletal.** Generalized joint hypermobility is always present in affected individuals, and many have recurrent joint (sub)luxations. Foot deformities (listed in Suggestive Findings) are present in the majority; hand abnormalities (acrogeric hands, mallet finger[s], clinodactyly, and brachydactyly) are less frequently reported [Demirdas et al 2017, Green et al 2020].

- Significant variability between both unrelated and related affected individuals in the severity of musculoskeletal symptoms and their effect on day-to-day function has been reported.
- The severity of symptoms in middle-aged individuals can range from joint hypermobility without complications to being wheelchair-bound due to severe and painful foot deformities, joint dislocations, and fatigue [Green et al 2020].



- More than half of affected individuals reported fatigue as an important feature (e.g., Demirdas et al [2017]: 14/17 individuals; Green et al [2020]: 14/20 individuals).
- Edema of the ankles and/or feet has been described in 14 of 56 individuals and could not be attributed to a cardiac etiology.

### Cardiovascular

- **Vascular fragility** has been reported in 15 of 56 (27%) affected individuals, with three of 56 (5%) experiencing major medical events due to vascular fragility.
  - Ten individuals experienced frequent subconjunctival hemorrhages.
  - Rupture of a right brachial vein was reported in a woman age 26 years [Micale et al 2019].
  - A man age 58 years had a thoraco-abdominal aortic aneurysm and aneurysm of both the common iliac artery and superior mesenteric artery [Demirdas et al 2017].
  - An affected individual who died in his sixth decade due to a bowel rupture had aneurysmal abdominal arteries on postmortem examination [Demirdas et al 2017].
  - One individual required surgery for two separate incidences of spontaneous compartment syndrome in his right and left arm at age 30 and 31 years, respectively [Green et al 2020].
  - One individual developed a spontaneous left-calf hematoma that had to be drained surgically [Green et al 2020].

This individual also developed a right-arm cephalic vein thrombosis and pulmonary embolism during admission for adrenal crisis.

She was subsequently started on anticoagulant therapy and shortly after required a hospital admission for spontaneous subcutaneous hematoma of the lower half of the body, causing acute anemia and requiring blood transfusion.

- **Valvular anomalies.** Mild valvular abnormalities, often involving the mitral valve, have been reported in nine of 56 (16%) of affected individuals.
- **Cardiomyopathy** was detected in three of 56 (5%) individuals (postpartum, dilated, and unspecified, respectively). It remains unclear if this represents rare co-occurrences of cardiomyopathy with *TNXB*-related cEDS or if cardiomyopathy is a rare feature of *TNXB*-related cEDS.

### Neuromuscular

- **Subjective muscle weakness** has been reported in about one third of affected individuals. Based partially on physiologic studies in affected individuals, a dose-effect relation of TNX levels and degree of neuromuscular involvement has been suggested [Castori & Voermans 2014].

The most elaborate study included ten individuals with *TNXB*-related cEDS among a group of 40 individuals with EDS of varying types [Voermans et al 2009].

Those with *TNXB*-related cEDS generally had moderate neuromuscular complaints, mild reduced sensation, muscle weakness, and functional impairment on physical examination.

- Moderate polyneuropathy and mild abnormal motor unit action potentials were seen on clinical neurophysiologic studies.
- Muscle ultrasound demonstrated increased echo intensity.
- Muscle biopsy showed mild myopathic changes in some affected individuals.
- It has been hypothesized that neuropathy may be linked to increased vulnerability of peripheral nerves to stretching/pressure due to TNX deficiency [Castori & Voermans 2014].

- **Atrophy of the muscles in the hands and feet** has been reported in 4% of affected individuals, although this feature was not assessed by Green et al [2020] in their cohort of 20 affected individuals. It is unclear whether this is a characteristic feature of *TNXB*-related cEDS.

### Gastrointestinal

- **Rupture.** Nine affected individuals have been reported with gastrointestinal fragility leading to a total of 14 gastrointestinal events. Four of these individuals had more than one gastrointestinal event in different locations, and four had a gastrointestinal event during an invasive procedure. One of these latter four had three events, two of which occurred after an invasive procedure. Age at which first gastrointestinal complications occurred varied from 36 years to 59 years. These findings imply a degree of tissue fragility with complications resulting from invasive procedures. The nine affected individuals and their respective events were as follows:
  - A man age 36 years with a perforation of a colonic diverticulum, who developed multiple abscesses requiring partial colectomy, which was complicated by a second small-bowel perforation [Lindor & Bristow 2005]
  - A man age 57 years who experienced an esophageal rupture possibly resulting from an ultrasound probe [Hendriks et al 2012]
  - A woman age 45 years who had a diverticular perforation of the sigmoid colon and duodenal perforation after ileus tube insertion [Sakiyama et al 2015]
  - An individual age 48 years who had a bowel perforation as a result of diverticulitis [Demirdas et al 2017]
  - An individual age 38 years with a colonic perforation during a colonoscopy [Brisset et al 2020]
  - A woman age 42 years who had a spontaneous perforation of the small bowel for which an intestinal specimen was reported to be "very fragile" [Rymen et al 2019]
  - Spontaneous transverse colon perforation at age 51 years followed by a second perforation of the small bowel three days postoperative [Green et al 2020]
  - Jejunal perforation at age 40 years [Green et al 2020]
  - Esophageal perforation at age 55 years during a gastroscopy, followed by a spontaneous small bowel perforation at age 56 years, and one small bowel perforation after a nasojejunal barium study at age 59 years [Green et al 2020]

Note: Demirdas et al [2017] reported death as a result of infection following bowel perforation of an individual in the sixth decade as unpublished data (not included in the cross-sectional analysis of 17 individuals represented in the publication).

- **Diverticular disease** has been noted in ten of 56 affected individuals. It is hypothesized that affected individuals may be more prone to structural defects along the walls of the gastrointestinal tract, which can predispose to diffuse diverticulosis, diverticulitis, and resulting bowel perforation as well as to perforation during invasive procedures and spontaneous perforation [Green et al 2020].
- **Gastrointestinal bleeding** has been reported in three of 56 affected individuals. It was not specified whether this occurred spontaneously or due to another gastrointestinal issue.

**Other tissue fragility.** Tracheal rupture possibly due to intubation has been reported in a woman age 41 years [Besselink-Lobanova et al 2010]. A woman age 47 years had extensive surgical emphysema within the subcutaneous tissues of her face and computed tomography (CT) scans of the sinuses revealed a defect of the left nasal cartilages anteriorly, allowing air to track into the soft tissues. It was felt that vigorous nose blowing had most likely been the cause of the emphysema. This may also point to tissue fragility in individuals with *TNXB*-related cEDS [Green et al 2020].

**Organ prolapse.** As in other types of EDS, vaginal/uterus/rectal prolapse are more frequently encountered and have been reported in 21% of individuals with *TNXB*-related cEDS.

## Genotype-Phenotype Correlations

No genotype-phenotype correlations have been identified.

## Nomenclature

Outdated terms for *TNXB*-related cEDS include tenascin-X deficient type of Ehlers-Danlos syndrome and tenascin-X deficiency.

## Prevalence

The prevalence of *TNXB*-related cEDS is unknown; 56 individuals from 44 families have been described in the literature. Two additional affected individuals were referenced by Demirdas et al [2017] as "unpublished data."

## Genetically Related (Allelic) Disorders

**CAH-X syndrome.** In 20%-30% of individuals with severe salt-wasting [21-hydroxylase-deficient congenital adrenal hyperplasia](#) (21-OHD CAH), deletions of *CYP21A2* are identified as a result of unequal crossover during meiosis. These deletions are categorized into two subtypes: CAH and CAH-X. There are three distinct CAH-X chimeras that impair both *CYP21A2* and *TNXB*. Biallelic CAH-X deletions lead to 21-OHD CAH with *TNXB*-related cEDS. In individuals with a monoallelic CAH-X deletion, joint hypermobility, pes planus, and hernias have been observed as well as congenital heart defects and other features [Miller & Merke 2018]. However, further studies in more individuals are needed to establish a causal relationship.

**Vesicoureteral reflux (VUR) 8** (OMIM [615963](#)). In a five-generation family with various members affected with VUR, Gbadegesin et al [2013] identified a heterozygous missense variant in *TNXB*. Subsequently, in 11 other families, *TNXB* was analyzed and a maternally inherited missense variant was identified in one affected individual; a voiding cystourethrogram was not performed on the mother to enable detection of vesicoureteral reflux. Currently, there is not enough evidence to support a causal relationship between *TNXB* variant(s) and VUR.

## Differential Diagnosis

**Table 3.** Genes and Disorders in the Differential Diagnosis of *TNXB*-Related Classic-Like Ehlers-Danlos Syndrome

Gene(s)	DiffDx Disorder	MOI	Features of DiffDx Disorder	
			Overlapping w/ <i>TNXB</i> -related cEDS	Distinguishing from <i>TNXB</i> -related cEDS
<i>ADAMTS2</i>	Dermatosparaxis EDS (OMIM <a href="#">225410</a> )	AR	Soft, doughy skin texture; skin hyperextensibility; GJH	Extreme skin fragility (usually > than in cEDS); redundant, almost lax skin; unusual craniofacial features; postnatal growth restriction; atrophic scarring
<i>AEBP1</i>	Classical-like EDS type 2 (OMIM <a href="#">618000</a> )	AR	GJH ± joint (sub)luxations; hyperextensible skin; easy bruising	Atrophic scarring; early-onset osteoporosis; <sup>1</sup> hair loss; dysmorphic features
<i>COL1A1</i> <i>COL5A1</i> <i>COL5A2</i>	Classic EDS	AD	GJH ± joint (sub)luxations; hyperextensible skin; easy bruising	Papyraceous &/or hemosiderotic scarring

Table 3. continued from previous page.

Gene(s)	DiffDx Disorder	MOI	Features of DiffDx Disorder	
			Overlapping w/ <i>TNXB</i> -related cEDS	Distinguishing from <i>TNXB</i> -related cEDS
<i>COL3A1</i> ( <i>COL1A1</i> <sup>2</sup> )	Vascular Ehlers-Danlos syndrome	AD	Easy bruising; (distal) joint hypermobility	Hyperextensible skin only seen in small subset of persons w/vEDS due to Glu>Lys substitutions <sup>3</sup>
<i>COL1A1</i> <i>COL1A2</i>	Arthrochalasia EDS (OMIM 130060, 617821)	AD	GJH; skin hyperextensibility; easy bruising	Atrophic scarring; congenital hip dislocation
<i>COL1A2</i>	Cardiac-valvular EDS (OMIM 225320)	AR	Skin hyperextensibility; easy bruising; (generalized) joint hypermobility	Severe progressive cardiac-valvular problems; atrophic scarring
<i>FKBP14</i>	<i>FKBP14</i> -related kyphoscoliotic EDS w/myopathy & neurosensory hearing loss	AR	GJH; skin hyperextensibility; easy bruising	Congenital muscle hypotonia; muscle atrophy; congenital hearing impairment
<i>PLOD1</i>	<i>PLOD1</i> -related kyphoscoliotic EDS	AR	GJH; skin hyperextensibility; easy bruising	Congenital muscle hypotonia; atrophic scarring

AD = autosomal dominant; AR = autosomal recessive; cEDS = classical-like Ehlers-Danlos syndrome; DiffDx = differential diagnosis; GJH = generalized joint hypermobility; MOI = mode of inheritance

1. Malfait et al [2020]

2. Pathogenic variants in *COL1A1* are listed as a rare cause of vascular Ehlers-Danlos syndrome in the 2017 international classification of the Ehlers-Danlos syndromes [Malfait et al 2017].

3. Ghali et al [2019]

**Hypermobile Ehlers-Danlos syndrome** (hEDS) should also be considered in the differential diagnosis of *TNXB*-related cEDS, as hEDS can be associated with mild atrophic scarring, generalized joint hypermobility with or without joint (sub)luxations, and easy bruising. However, the absence of clearly hyperextensible skin in hEDS distinguishes this disorder from *TNXB*-related cEDS. The diagnosis of hEDS is based entirely on clinical evaluation and family history. The molecular basis of hEDS is unknown.

## Management

No consensus clinical practice guidelines for *TNXB*-related classical-like Ehlers-Danlos syndrome (cEDS) have been published.

## Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with *TNXB*-related cEDS, the evaluations summarized in Table 4 (if not performed as part of the evaluation that led to the diagnosis) are recommended.

**Table 4.** Recommended Evaluations Following Initial Diagnosis in Individuals with *TNXB*-Related Classical-Like Ehlers-Danlos Syndrome

System/Concern	Evaluation	Comment
<b>Musculoskeletal</b>	Rheumatologist / physical medicine & rehab / PT & OT / podiatrist eval	To incl assessment of: <ul style="list-style-type: none"> <li>• Tone &amp; joint laxity</li> <li>• Mobility, ADL, &amp; need for adaptive devices</li> <li>• Need for PT (to improve strength and tone) &amp;/or OT (to improve fine motor skills)</li> <li>• Podiatry assessment for foot abnormalities</li> </ul> Avoidance of sports that place heavy strain on joints also recommended (See Agents/Circumstances to Avoid.)
<b>Cardiovascular</b>	Baseline echocardiogram	To assess for structural cardiac abnormalities & aortic dimensions
<b>Hematologic</b>	Consider referral to hematologist for those w/ recurrent severe bruising w/swelling.	Further lab studies (e.g., clotting studies) may be requested; per hematologist
<b>Genetic counseling</b>	By genetics professionals <sup>1</sup>	To inform affected persons & their families re nature, MOI, & implications of <i>TNXB</i> -related cEDS to facilitate medical & personal decision making
<b>Family support &amp; resources</b>	Assess need for: <ul style="list-style-type: none"> <li>• Community or online resources such as <a href="#">Parent to Parent</a>;</li> <li>• Social work involvement for parental support.</li> </ul>	

ADL = activities of daily living; cEDS = classical-like Ehlers-Danlos syndrome; MOI = mode of inheritance; OT = occupational therapy; PT = physical therapy

1. Medical geneticist, certified genetic counselor, certified advanced genetic nurse

## Treatment of Manifestations

**Table 5.** Treatment of Manifestations in Individuals with *TNXB*-Related Classical-Like Ehlers-Danlos Syndrome

Manifestation/Concern	Treatment	Considerations/Other
<b>Hypotonia / Gross motor delay</b>	Standard treatment by PT	Non-weight-bearing muscular exercise, such as swimming, is useful to promote muscular development & coordination.
<b>Joint laxity/ dislocations</b>	For recommendations on treatment, see <a href="#">Hypermobile EDS</a> .	Surgical stabilization of joints may lead to minimal or only temporary improvement.
<b>Joint pain</b>	<ul style="list-style-type: none"> <li>• Non-weight-bearing exercise</li> <li>• For recommendations on pain medication, see <a href="#">Hypermobile EDS</a>.</li> <li>• Careful selection of analgesic medication is recommended in light of ↑ risks of diverticulitis &amp; diverticular bleeding in users of aspirin or NSAIDs.</li> </ul>	<ul style="list-style-type: none"> <li>• Consider referral to rheumatologist &amp;/or pain mgmt specialist or clinic.</li> <li>• Avoid use of opioid medication for chronic pain; it does not relieve pain long term &amp; can → addiction.</li> <li>• Long-term chronic pain may → need for mental health services.</li> </ul>
<b>Subjective muscle weakness</b>	Standard eval & treatment per neurologist	
<b>Vessel/organ rupture</b>	Prompt assessment & mgmt in tertiary care center	
<b>Cardiac/valvular abnormalities</b>	Standard treatment per cardiologist	

Table 5. continued from previous page.

Manifestation/Concern	Treatment	Considerations/Other
<b>Easy bruising</b>	Ascorbic acid (vitamin C) may ↓ easy bruising but has no effect on primary findings of skin hyperextensibility or joint hypermobility.	In general, a dose of 2 g/day is recommended for adults, w/proportionally ↓ doses for children; however, there is no limitation.
	DDAVP® may be useful to normalize bleeding time.	May be beneficial in case of bruising or epistaxis, or before procedures such as dental extractions
	See also <a href="#">Classic EDS</a> .	

EDS = Ehlers-Danlos syndrome; NSAID = nonsteroidal anti-inflammatory drug

## Prevention of Primary Manifestations

For recommendations on prevention of primary manifestations of joint laxity and dislocations as well as joint pain, see [Hypermobile Ehlers-Danlos Syndrome, Prevention of Primary Manifestations](#).

Table 6. Prevention of Primary Manifestations in Individuals with *TNXB*-Related Classical-Like Ehlers-Danlos Syndrome

Manifestation/Concern	Preventive Measure	Considerations/Other
<b>Joint dislocation/pain</b>	Maintenance of healthy body weight through diet & appropriate exercise	Exercise is typically low impact.
<b>Bleeding/bruising</b>	Ascorbic acid (vitamin C) &/or DDAVP®	See <b>Easy bruising</b> in Table 5.
<b>Abdominal pain</b>	Low threshold for referral to gastroenterologist for eval due to ↑ risk of bowel rupture	Avoidance of endoscopy or colonoscopy unless absolutely necessary
<b>Tissue rupture</b>	Avoidance of invasive procedures unless absolutely necessary	Tissue rupture has been reported during intubation, endoscopy, & colonoscopy.
<b>Pressure or stretch neuropathies</b>	Special attention during general anesthesia to provide adequate positioning & support <sup>1</sup>	Tracheal rupture can occur w/intubation.
<b>Education of providers/caregivers</b>	Consider carrying medical info or wearing jewelry (e.g., emergency letter &/or MedicAlert® bracelet) denoting ↑ risk of tissue fragility.	

1. Voermans et al [2006]

## Surveillance

Table 7. Recommended Surveillance for Individuals with *TNXB*-Related Classical-Like Ehlers-Danlos Syndrome

System/Concern	Evaluation	Frequency
<b>Musculoskeletal</b>	Coordination of care & follow up ideally lies w/rheumatologist, pain mgmt clinic, &/or specialized EDS services, if available. <sup>1</sup>	Based on individual assessment & determined by responsible health care professional

EDS = Ehlers-Danlos syndrome

1. Green et al [2020]

## Agents/Circumstances to Avoid

The following should be avoided:

- Sports with heavy joint strain (e.g., contact sports, fighting sports, football, running)
- Invasive procedures such as intubation, endoscopy, and/or colonoscopy unless essential because of reported tissue fragility of the trachea, esophagus, and small and large bowels

- Acetylsalicylate (aspirin) and long-term use of nonsteroidal anti-inflammatory drugs because of elevated risks of diverticulitis and diverticular bleeding
- The use of opioid medication for chronic pain, which does not lead to long-term pain relief and has the potential for addiction issues

## Evaluation of Relatives at Risk

It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk relatives of an affected individual in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

## Pregnancy Management

It is important that the obstetrician and midwives be made aware of the diagnosis of *TNXB*-related cEDS during a pregnancy. Reported pregnancy and postpartum issues in affected women include miscarriage, premature rupture of membranes, post- or peripartum hemorrhage, and prolapse of the rectum, vagina, and/or uterus [Green et al 2020].

Gynecologic follow up during pregnancy can be considered. Specialist delivery is strongly advised in view of the reported trachea rupture during intubation and esophagus rupture after insertion of a transesophageal ultrasound probe. These complications emphasize the need for careful handling of pregnant women with *TNXB*-related cEDS, especially in emergency situations [Brady et al 2017].

## Therapies Under Investigation

Search [ClinicalTrials.gov](https://clinicaltrials.gov) in the US and [EU Clinical Trials Register](https://clinicaltrialsregister.eu) in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

## Genetic Counseling

*Genetic counseling is the process of providing individuals and families with information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members; it is not meant to address all personal, cultural, or ethical issues that may arise or to substitute for consultation with a genetics professional. —ED.*

## Mode of Inheritance

*TNXB*-related classical-like Ehlers-Danlos syndrome (cEDS) is inherited in an autosomal recessive manner.

## Risk to Family Members

### Parents of a proband

- The parents of an affected individual are obligate heterozygotes (i.e., presumed to be carriers of one *TNXB* pathogenic variant based on family history).
- Molecular genetic testing is recommended for the parents of a proband to confirm that both parents are heterozygous for a *TNXB* pathogenic variant and to allow reliable recurrence risk assessment. If a pathogenic variant is detected in only one parent, the following possibilities should be considered:

- One of the pathogenic variants identified in the proband occurred as a *de novo* event in the proband or as a postzygotic *de novo* event in a mosaic parent [Jónsson et al 2017].
- Uniparental isodisomy for the parental chromosome with the pathogenic variant resulted in homozygosity for the pathogenic variant in the proband.
- Heterozygotes may or may not be asymptomatic. Zweers et al [2003] investigated 20 heterozygous family members. All had significantly reduced serum TNX levels (compatible with heterozygote status). Clinical examination revealed generalized joint hypermobility and recurring joint dislocations and chronic joint pain in the majority of heterozygous females (nine of 14). Further investigations are needed to elucidate a possible role of reduced TNX levels and joint hypermobility. Skin hyperextensibility and easy bruising were absent in heterozygotes; heterozygotes as such do not fulfill the major criteria for *TNXB*-related cEDS and are not at risk of developing *TNXB*-related cEDS.

### Sibs of a proband

- If both parents are known to be heterozygous for a *TNXB* pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the familial pathogenic variants.
- Although sibs with biallelic *TNXB* pathogenic variants are expected to fulfill the major criteria for *TNXB*-related cEDS, intrafamilial variability has been observed and the severity of related manifestations (e.g., musculoskeletal problems) can be variable.
- Heterozygotes may or may not be asymptomatic (see **Parents of a proband**).

**Offspring of a proband.** The offspring of an individual with *TNXB*-related cEDS are obligate heterozygotes (carriers) for a pathogenic variant in *TNXB*.

**Other family members.** Each sib of the proband's parents is at a 50% risk of being a carrier of a *TNXB* pathogenic variant.

## Carrier (Heterozygote) Detection

Carrier testing for at-risk relatives requires prior identification of the *TNXB* pathogenic variants in the family.

## Related Genetic Counseling Issues

See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.

### Family planning

- The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
- It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.

## Prenatal Testing and Preimplantation Genetic Testing

Once the *TNXB* pathogenic variants have been identified in an affected family member, prenatal and preimplantation genetic testing are possible.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.



## Resources

GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click [here](#).

- **Ehlers-Danlos Society - Europe**  
United Kingdom  
**Phone:** +44 203 887 6132
- **Ehlers-Danlos Support UK**  
United Kingdom  
**Phone:** 0208 736 5604; 0800 9078518  
[ehlers-danlos.org](http://ehlers-danlos.org)
- **The Ehlers-Danlos Society**  
**Phone:** 410-670-7577  
[ehlers-danlos.com](http://ehlers-danlos.com)
- **MedlinePlus**  
Ehlers-Danlos Syndrome
- **DICE EDS and HSD Global Registry**  
[ehlers-danlos.com/eds-global-registry](http://ehlers-danlos.com/eds-global-registry)

## Molecular Genetics

Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.

**Table A.** TNXB-Related Classical-Like Ehlers-Danlos Syndrome: Genes and Databases

Gene	Chromosome Locus	Protein	Locus-Specific Databases	HGMD	ClinVar
<i>TNXB</i>	6p21.33-p21.32	Tenascin-X	<a href="#">TNXB homepage - LOVD - Australian Human Variome Project Ehlers Danlos Syndrome Variant Database (TNXB)</a>	<a href="#">TNXB</a>	<a href="#">TNXB</a>

Data are compiled from the following standard references: gene from [HGNC](#); chromosome locus from [OMIM](#); protein from [UniProt](#). For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click [here](#).

**Table B.** OMIM Entries for TNXB-Related Classical-Like Ehlers-Danlos Syndrome ([View All in OMIM](#))

600985	TENASCIN XB; TNXB
606408	EHLERS-DANLOS SYNDROME, CLASSIC-LIKE, 1; EDSCLL1

## Molecular Pathogenesis

*TNXB* encodes tenascin-X (TN-X), a glycoprotein of the extracellular matrix. Biallelic pathogenic variants result in a loss of the functional protein product and the characteristic clinical features. Pathogenic splice site or nonsense *TNXB* variants can lead to nonsense-mediated decay of the mutated RNA and result in complete absence of TN-X. Pathogenic missense variants may result in misfolding of the protein. Individuals with a

molecularly confirmed diagnosis of *TNXB*-related classical-like Ehler-Danlos syndrome (clEDS) can have (1) intragenic pathogenic variants, (2) *TNXB* whole-gene or small deletions, or (3) contiguous deletions of *TNXB* and *CYP21A2*.

*TNXB* and *CYP21A2* (associated with congenital adrenal hyperplasia) are located within the human leukocyte antigen histocompatibility complex at 6p23.1 alongside their homologous pseudogenes, *TNXA* and *CYP21A1P*. This region is prone to meiotic nonhomologous recombination resulting in gene conversions (exchange of DNA sequences between gene and pseudogene). Three types of *TNXA/TNXB* gene conversions have been identified [Morissette et al 2015]: (1) CAH-X chimera 1 (CH-1) has *TNXB* exons 35-44 replaced with *TNXA* and is characterized by the c.11435\_11524+30del variant; (2) CAH-X chimera 2 (CH-2) has *TNXB* exons 40-44 replaced with *TNXA* and is characterized by the *TNXA*-derived c.12174C>G (p.Cys4058Trp) variant; (3) CAH-X chimera 3 (CH-3) has *TNXB* exons 41-44 replaced by *TNXA* and is characterized by three *TNXA*-derived missense variants. The exact pathogenic mechanism of the c.12174C>G (p.Cys4058Trp) variant is unknown, but the variant affects a cysteine residue that is predicted to form a disulfide bond, stabilizing tertiary protein structure [Demirdas et al 2017]. *TNXB*-related clEDS is often caused by gene conversion events, which are the most common recurrent mechanism of pathogenicity [Green et al 2020].

**Mechanism of disease causation.** Loss of function

***TNXB*-specific laboratory technical considerations.** Molecular genetic testing may be complicated by the presence of pseudogene *TNXA*, which has greater than 97% homology to the 3' end (exons 32-44) of *TNXB*. As such, exon and intron sequences are (almost) identical in the gene and pseudogene [Demirdas et al 2017].

**Table 8.** Notable *TNXB* Pathogenic Variants

Reference Sequences	DNA Nucleotide Change	Predicted Protein Change	Comment
<a href="#">NG_008337.2</a>	c.11435_11524+30del		Due to gene conversion event (CH-1)
<a href="#">NM_019105.8</a> <a href="#">NP_061978.6</a>	c.12174C>G	p.Cys4058Trp	Due to gene conversion event (CH-2)

Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

*GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([varnomen.hgvs.org](http://varnomen.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

## Chapter Notes

### Revision History

- 15 September 2022 (ma) Review posted live
- 24 September 2021 (fvd) Original submission

## References

### Literature Cited

- Besselink-Lobanova A, Maandag NJ, Voermans NC, van der Heijden HF, van der Hoeven JG, Heunks LM. Trachea rupture in tenascin-X-deficient type Ehlers-Danlos syndrome. *Anesthesiology*. 2010;113:746–9. PubMed PMID: 20693885.
- Brady AF, Demirdas S, Fournel-Gigleux S, Ghali N, Giunta C, Kapferer-Seebacher I, Kosho T, Mendoza-Londono R, Pope MF, Rohrbach M, Van Damme T, Vandersteen A, van Mourik C, Voermans N, Zschocke J,

- Malfait F. The Ehlers-Danlos syndromes, rare types. *Am J Med Genet C Semin Med Genet.* 2017;175:70–115. PubMed PMID: 28306225.
- Brisset M, Metay C, Carlier RY, Badosa C, Marques C, Schalkwijk J, vanVlijmen-Willems I, Jimenez-Mallebrera C, Keren B, Jobic V, Laforêt P, Malfatti E. Biallelic mutations in Tenascin-X cause classical-like Ehlers-Danlos syndrome with slowly progressive muscular weakness. *Neuromuscul Disord.* 2020;30:833–8. PubMed PMID: 32988710.
- Burch GH, Gong Y, Liu W, Dettman RW, Curry CJ, Smith L, Miller WL, Bristow J. Tenascin-X deficiency is associated with Ehlers-Danlos syndrome. *Nat Genet.* 1997;17:104–8. PubMed PMID: 9288108.
- Castori M, Voermans NC. Neurological manifestations of Ehlers-Danlos syndrome(s): a review. *Iran J Neurol.* 2014;13:190–208. PubMed PMID: 25632331.
- Chen W, Perritt AF, Morissette R, Dreiling JL, Bohn MF, Mallappa A, Xu Z, Quezado M, Merke DP. Ehlers Danlos syndrome caused by biallelic TNXB variants in patients with congenital adrenal hyperplasia. *Hum Mutat.* 2016;37:893–7. PubMed PMID: 27297501.
- Demirdas S, Dulfer E, Robert L, Kempers M, van Beek D, Micha D, van Engelen BG, Hamel B, Schalkwijk J, Loeys B, Maugeri A, Voermans NC. Recognizing the tenascin-X deficient type of Ehlers-Danlos syndrome: a cross-sectional study in 17 patients. *Clin Genet.* 2017;91:411–25. PubMed PMID: 27582382.
- Gbadegesin RA, Brophy PD, Adeyemo A, Hall G, Gupta IR, Hains D, Bartkowiak B, Rabinovich CE, Chandrasekharappa S, Homstad A, Westreich K, Wu G, Liu Y, Holanda D, Clarke J, Lavin P, Selim A, Miller S, Wiener JS, Ross SS, Foreman J, Rotimi C, Winn MP. TNXB mutations can cause vesicoureteral reflux. *J Am Soc Nephrol.* 2013;24:1313–22. PubMed PMID: 23620400.
- Ghali N, Baker D, Brady AF, Burrows N, Cervi E, Cilliers D, Frank M, Germain DP, Hulmes DJS, Jacquemont ML, Kannu P, Lefroy H, Legrand A, Pope FM, Robertson L, Vandersteen A, von Klemperer K, Warburton R, Whiteford M, van Dijk FS. Atypical COL3A1 variants (glutamic acid to lysine) cause vascular Ehlers-Danlos syndrome with a consistent phenotype of tissue fragility and skin hyperextensibility. *Genet Med.* 2019;21:2081–91. PubMed PMID: 30837697.
- Green C, Ghali N, Akilapa R, Angwin C, Baker D, Bartlett M, Bowen J, Brady AF, Brock J, Chamberlain E, Cheema H, McConnell V, Crookes R, Kazkaz H, Johnson D, Pope FM, Vandersteen A, Sobey G, van Dijk FS. Classical-like Ehlers-Danlos syndrome: a clinical description of 20 newly identified individuals with evidence of tissue fragility. *Genet Med.* 2020;22:1576–82. PubMed PMID: 32572181.
- Hendriks AGM, Voermans NC, Schalkwijk J, Hamel BC, van Rossum MM. Well-defined clinical presentation of Ehlers-Danlos syndrome in patients with tenascin-X deficiency: a report of four cases. *Clin Dysmorphol.* 2012;21:15–8. PubMed PMID: 21959861.
- Jónsson H, Sulem P, Kehr B, Kristmundsdottir S, Zink F, Hjartarson E, Hardarson MT, Hjorleifsson KE, Eggertsson HP, Gudjonsson SA, Ward LD, Arnadottir GA, Helgason EA, Helgason H, Gylfason A, Jonasdottir A, Jonasdottir A, Rafnar T, Frigge M, Stacey SN, Th Magnusson O, Thorsteinsdottir U, Masson G, Kong A, Halldorsson BV, Helgason A, Gudbjartsson DF, Stefansson K. Parental influence on human germline de novo mutations in 1,548 trios from Iceland. *Nature.* 2017;549:519–22. PubMed PMID: 28959963.
- Lindor NM, Bristow J. Tenascin-X deficiency in autosomal recessive Ehlers-Danlos syndrome. *Am J Med Genet A.* 2005;135:75–80. PubMed PMID: 15793839.
- Malfait F, Castori M, Francomano CA, Giunta C, Kosho T, Byers PH. The Ehlers-Danlos syndromes. *Nat Rev Dis Primers.* 2020;6:64. PubMed PMID: 32732924.
- Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, Bloom L, Bowen JM, Brady AF, Burrows NP, Castori M, Cohen H, Colombi M, Demirdas S, De Backer J, De Paepe A, Fournel-Gigleux S, Frank M, Ghali N, Giunta C, Grahame R, Hakim A, Jeunemaitre X, Johnson D, Juul-Kristensen B, Kapferer-Seebacher I, Kazkaz H, Kosho T, Lavalley ME, Levy H, Mendoza-Londono R, Pepin M, Pope FM, Rinstein E, Robert L,

- Rohrbach M, Sanders L, Sobey GJ, Van Damme T, Vandersteen A, van Mourik C, Voermans N, Wheeldon N, Zschocke J, Tinkle B. The 2017 international classification of the Ehlers–Danlos syndromes. *Am J Med Genet C Semin Med Genet.* 2017;175:8–26. PubMed PMID: 28306229.
- Micale L, Guarnieri V, Augello B, Palumbo O, Agolini E, Sofia VM, Mazza T, Novelli A, Carella M, Castori M. Novel TNXB variants in two Italian patients with classical-like Ehlers-Danlos syndrome. *Genes (Basel).* 2019;10:967. PubMed PMID: 31775249.
- Miller WL, Merke DP. Tenascin-X, congenital adrenal hyperplasia, and the CAH-X syndrome. *Horm Res Paediatr.* 2018;89:352–61. PubMed PMID: 29734195.
- Morissette R, Chen W, Perritt AF, Dreiling JL, Arai AE, Sachdev V, Hannoush H, Mallappa A, Xu Z, McDonnell NB, Quezado M, Merke DP. Broadening the spectrum of Ehlers Danlos syndrome in patients with congenital adrenal hyperplasia. *J Clin Endocrinol Metab.* 2015;100:E1143–52. PubMed PMID: 26075496.
- O'Connell M, Burrows NP, van Vlijmen-Willems MJJ, Clark SM. Schalkwijk. Tenascin-X deficiency and Ehlers-Danlos syndrome: a case report and review of the literature. *Br J Dermatol.* 2010;163:1340–5. PubMed PMID: 20649799.
- Pénisson-Besnier I, Allamand V, Beurrier P, Martin L, Schalkwijk J, van Vlijmen-Willems I, Gartioux C, Malfait F, Syx D, Macchi L, Marcorelles P, Arbeille B, Croué A, De Paepe A, Dubas F. Compound heterozygous mutations of the TNXB gene cause primary myopathy. *Neuromuscul Disord.* 2013;23:664–9. PubMed PMID: 23768946.
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015;17:405–24. PubMed PMID: 25741868.
- Rymen D, Ritelli M, Zoppi N, Cinquina V, Giunta C, Rohrbach M, Colombi M. Clinical and molecular characterization of classical-like Ehlers-Danlos syndrome due to a novel TNXB variant. *Genes (Basel).* 2019;10:843. PubMed PMID: 31731524.
- Sakiyama T, Kubo A, Sasaki T, Yamada T, Yabe N, Matsumoto K, Futei Y. Recurrent gastrointestinal perforation in a patient with Ehlers-Danlos syndrome due to tenascin-X deficiency. *J Dermatol.* 2015;42:511–4. PubMed PMID: 25772043.
- Schalkwijk J, Zweers MC, Steijlen PM, Dean WB, Taylor G, van Vlijmen IM, van Haren B, Miller WL, Bristow J. A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. *N Engl J Med.* 2001;345:1167–75. PubMed PMID: 11642233.
- Stenson PD, Mort M, Ball EV, Chapman M, Evans K, Azevedo L, Hayden M, Heywood S, Millar DS, Phillips AD, Cooper DN. The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting. *Hum Genet.* 2020;139:1197–207. PubMed PMID: 32596782.
- Voermans NC, Drost G, van Kampen A, Gabreëls-Festen AA, Lammens M, Hamel BC, Schalkwijk J, van Engelen BG. Recurrent neuropathy associated with Ehlers-Danlos syndrome. *J Neurol.* 2006;253:670–1. PubMed PMID: 16311893.
- Voermans NC, Jenniskens GJ, Hamel BC, Schalkwijk J, Guicheney P, van Engelen BG. Ehlers-Danlos syndrome due to tenascin-X deficiency: muscle weakness and contractures support overlap with collagen VI myopathies. *Am J Med Genet A.* 2007;143A:2215–9. PubMed PMID: 17702048.
- Voermans NC, van Alfen N, Pillen S, Lammens M, Schalkwijk J, Zwarts MJ, van Rooij IA, Hamel BC, van Engelen BG. Neuromuscular involvement in various types of Ehlers-Danlos syndrome. *Ann Neurol.* 2009;65:687–97. PubMed PMID: 19557868.

- Watanabe S, Ito Y, Samura O, Nakano H, Sawamura D, Asahina A, Itoh M. Novel gross deletion mutation c.-105\_4042+498del in the TNXB gene in a Japanese woman with classical-like Ehlers-Danlos syndrome: a case of uneventful pregnancy and delivery. *J Dermatol.* 2021;48:e227–e228. PubMed PMID: 33721335.
- Zweers MC, Bristow J, Steijlen PM, Dean WB, Hamel BC, Otero M, Kucharekova M, Boezeman JB, Schalkwijk J. Haploinsufficiency of TNXB is associated with hypermobility type of Ehlers-Danlos syndrome. *Am J Hum Genet.* 2003;73:214–7. PubMed PMID: 12865992.

## License

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<http://www.genereviews.org/>) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the [GeneReviews® Copyright Notice and Usage Disclaimer](#). No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the [GeneReviews® Copyright Notice and Usage Disclaimer](#).

For questions regarding permissions or whether a specified use is allowed, contact: [admasst@uw.edu](mailto:admasst@uw.edu).